← Back to Search

Exercise Program for Parkinson's Disease

N/A
Recruiting
Led By Fay Horak, PhD, PT
Research Sponsored by Oregon Health and Science University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of idiopathic PD from movement disorders neurologist with the United Kingdom Brain Bank criteria of bradykinesia with 1 or more of the following - rest tremor, rigidity, and balance problems not from visual, vestibular, cerebellar or proprioceptive conditions
Hoehn & Yahr stages II-IV
Must not have
Major musculoskeletal or neurological disorders, structural brain disease, epilepsy, acute illness or health history, other than PD
MoCA ≤ 21 or inability to follow directions
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 52 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial tests TURN-IT, an exercise program for people with Parkinson's Disease who have had falls. The program aims to improve turning ability by addressing stiffness, balance, movement speed, and changing movements.

Who is the study for?
This trial is for people aged 55-85 with Parkinson's Disease who have fallen in the past year. They must respond to levodopa treatment, be at certain stages of the disease, and can't have other major health issues or recent medication changes. Participants need to commit to attending exercise sessions without altering their medications or exercise habits.
What is being tested?
The TURN-IT program focuses on improving turning movements in those with Parkinson's by addressing common physical limitations caused by the disease. The study will compare a group doing this special exercise three times a week for six weeks against a control group that does not receive any intervention.
What are the potential side effects?
Since TURN-IT is an exercise program, potential side effects may include muscle soreness, fatigue, and increased risk of falls during practice. However, these are typical responses to physical activity and should be temporary as participants adapt.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have Parkinson's diagnosed by a specialist, with symptoms like slow movement, tremor, stiffness, or balance issues not caused by other conditions.
Select...
My Parkinson's disease is at a moderate to advanced stage.
Select...
I am between 55 and 85 years old.
Select...
I have fallen at least once in the last year.
Select...
My condition improves with levodopa treatment.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have major musculoskeletal, neurological disorders, or epilepsy, except for Parkinson's Disease.
Select...
I may have difficulty understanding or following instructions.
Select...
I cannot stand or walk for 2 minutes without help.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~52 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 52 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in variability in number of steps to complete a turn
Secondary study objectives
Change in Falls Efficacy Scale International
Change in lateral trunk range
Change in number of steps to complete a turn
+7 more
Other study objectives
Change in Activities-Specific Balance Confidence Scale
Change in Parkinson's Disease Questionnaire-39
Change in Unified Parkinson's Disease Rating Scale, Part III
+11 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: TURN-IT groupExperimental Treatment1 Intervention
Participants in the treatment group will attend supervised, 1-hour classes, 3 times per week for 6 weeks, one-on-one with the same exercise trainer, overseen by a physical therapist investigator.
Group II: No Intervention Control GroupActive Control1 Intervention
Participants in this group will be tested at baseline and 6 weeks later. They will go about their normal daily life during the 6 week period.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Parkinson's Disease (PD) include dopaminergic therapies, such as levodopa and dopamine agonists, which work by replenishing or mimicking dopamine to improve motor function. MAO B inhibitors help to prolong the effect of dopamine by inhibiting its breakdown. Nonpharmacologic treatments, particularly exercise programs like TURN-IT, focus on improving motor symptoms by addressing physiological constraints such as axial rigidity, bradykinesia, and balance issues. These exercise interventions are crucial as they can enhance mobility, reduce fall risk, and improve overall quality of life for PD patients by promoting neuroplasticity and physical conditioning.
Dance for Parkinson's-The effects on whole body co-ordination during turning around.

Find a Location

Who is running the clinical trial?

Oregon Health and Science UniversityLead Sponsor
1,006 Previous Clinical Trials
7,414,013 Total Patients Enrolled
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
2,063 Previous Clinical Trials
2,746,279 Total Patients Enrolled
Fay Horak, PhD, PTPrincipal InvestigatorOregon Health and Science University

Media Library

Turning Boot Camp exercise program Clinical Trial Eligibility Overview. Trial Name: NCT04897256 — N/A
Parkinson's Disease Research Study Groups: No Intervention Control Group, TURN-IT group
Parkinson's Disease Clinical Trial 2023: Turning Boot Camp exercise program Highlights & Side Effects. Trial Name: NCT04897256 — N/A
Turning Boot Camp exercise program 2023 Treatment Timeline for Medical Study. Trial Name: NCT04897256 — N/A
~7 spots leftby May 2025